Trials / Recruiting
RecruitingNCT06991881
Eosinophilic Esophagitis: Towards Improved Management
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
The current project aims to improve the care for children and adolescents with eosinophilic esophagitis in a collaborative effort involving pediatric units at Oslo Unversity Hospital and Helse Bergen, Norway. Existing and new non-invasive biomarkers will be explored systematically, aiming to reduce the number of endoscopies and time on restricted diet.
Detailed description
The overall aim of the current proposal is to improve the care for children and adolescents with EoE and reduce the need for complex elimination diets and repeated endoscopies. Our objectives are to determine whether 1. at diagnosis the following are predictive for response to food elimination: 1. history of atopy, symptoms after food intake 2. eosinophil counts in biopsies and peripheral blood 3. total IgE, specific IgE, eosinophilic granula proteins, eosinophil progenitor cells in blood 4. key cytokines (Eotaxin-3, IL-5, IL-13) 5. eosinophil derived neurotoxin/EDN in oesophageal aspirates, blood samples and feces 6. circulating microRNAs 2. at follow-up biomarkers collected by non-invasive methods can predict endoscopic and histologic healing 1. eosinophil counts in esophageal brushes and peripheral blood 2. total IgE, specific IgE, eosinophilic granula protein, eosinophil progenitor cells 3. circulating cytokines like eotaxin-3, IL-5, IL-13 4. eosinophil derived neurotoxin/EDN in esophageal brushes, blood samples and feces 5. circulating microRNAs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biobank sampling for new biomarkers | Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies. |
Timeline
- Start date
- 2023-10-31
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2025-05-28
- Last updated
- 2025-05-28
Locations
2 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT06991881. Inclusion in this directory is not an endorsement.